Search

Author/Creator Cinieri, S

2. 1795PBald is beautiful: No more. The stigma of alopecia during chemotherapy: Brindisi oncology department experience. (23rd October 2018)

Authors:
Loparco, D; Orlando, L; Caloro, M; Fedele, P; Schiavone, P; Quaranta, A; Caliolo, C; Cinefra, M; Ferrara, P; Falcone, L L; Capone, V; Destro, C; Morleo, A; Ricco, A; Bonuso, V; Lotti, G; D'amico, M; Rizzo, P; Marino, A; Cinieri, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Issue 2 (February 2021)

Authors:
Pignata, Sandro; Lorusso, Domenica; Joly, Florence; Gallo, Ciro; Colombo, Nicoletta; Sessa, Cristiana; Bamias, Aristotelis; Salutari, Vanda; Selle, Frédèric; Frezzini, Simona; De Giorgi, Ugo; Pautier, Patricia; Bologna, Alessandra; Orditura, Michele; Dubot, Coraline; Gadducci, Angiolo; Mammoliti,...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 2(2021)
Page Start:
267
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA 2Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial. (13th May 2019)

Authors:
Guarneri, V; Cinieri, S; Orlando, L; Bengala, C; Mariani, G; Bisagni, G; Frassoldati, A; Zamagni, C; Salvo, G De; Conte, P F
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. (23rd October 2018)

Authors:
Morano, F; Corallo, S; Di Bartolomeo, M; Lonardi, S; Cremolini, C; Rimassa, L; Sartore Bianchi, A; Murialdo, R; Zaniboni, A; Adamo, V; Tomasello, G; Tampellini, M; Fanchini, L; Schirripa, M; Clavarezza, M; Petrelli, F; Longarini, R; Cinieri, S; de Braud, F G M; Pietrantonio, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

Authors:
Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

Authors:
Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. (11th June 2018)

Authors:
Malorni, L; Curigliano, G; Minisini, A M; Cinieri, S; Tondini, C A; D'Hollander, K; Arpino, G; Bernardo, A; Martignetti, A; Criscitiello, C; Puglisi, F; Pestrin, M; Sanna, G; Moretti, E; Risi, E; Biagioni, C; McCartney, A; Boni, L; Buyse, M; Migliaccio, I
Journal:
Annals of oncology
Issue:
Volume 29:Number 8(2018)
Page Start:
1748
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. (16th February 2018)

Authors:
Piccirillo, M C; Scambia, G; Bologna, A; Signoriello, S; Vergote, I; Baumann, K; Lorusso, D; Murgia, V; Sorio, R; Ferrandina, G; Sacco, C; Cormio, G; Breda, E; Cinieri, S; Natale, D; Mangili, G; Pisano, C; Cecere, S C; Di Napoli, M; Salutari, V
Journal:
Annals of oncology
Issue:
Volume 29:Number 5(2018)
Page Start:
1189
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗